Beta-testing of PI3-kinase inhibitors: is beta better?

Cancer Discov. 2012 May;2(5):393-4. doi: 10.1158/2159-8290.CD-12-0122.


Although it has been known for some time that PTEN-null tumors require expression of the p110β isoform of phosphoinositide 3-kinase for growth, the corollary demonstration that small-molecule inhibitors of p110β are effective drugs for such tumors has not been shown. This has now been rectified by the demonstration that the TGX221 analogue KIN-193 is effective in mouse xenografts of HCC70 and PC3 human tumor cell lines.

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Humans
  • Male
  • Neoplasms / drug therapy*
  • Phosphoinositide-3 Kinase Inhibitors*


  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors